Contineum Therapeutics, Inc. Increase (Decrease) in Accounts Payable
Contineum Therapeutics, Inc. (CTNM) reported Increase (Decrease) in Accounts Payable of -$500.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsPayable · last filed 2026-07-30
- Contineum Therapeutics, Inc. increase (decrease) in accounts payable for the quarter ending 2026-06-30 was -$990.00K.
- Contineum Therapeutics, Inc. increase (decrease) in accounts payable for the quarter ending 2026-03-31 was $490.00K, a 73.28% decline year-over-year.
- Contineum Therapeutics, Inc. increase (decrease) in accounts payable for the quarter ending 2025-12-31 was $162.00K, a 57.14% decline year-over-year.
- Contineum Therapeutics, Inc. increase (decrease) in accounts payable for the quarter ending 2025-09-30 was -$1.22M, a 284.16% decline year-over-year.
- Contineum Therapeutics, Inc. increase (decrease) in accounts payable for fiscal 2025 was -$869.00K, a 176.16% decline from fiscal 2024.
- Contineum Therapeutics, Inc. increase (decrease) in accounts payable for fiscal 2024 was $1.14M.
- Contineum Therapeutics, Inc. increase (decrease) in accounts payable for fiscal 2023 was $0.00.
| Period end | Increase (Decrease) in Accounts Payable 3 month | Increase (Decrease) in Accounts Payable 6 month | Increase (Decrease) in Accounts Payable 9 month | Increase (Decrease) in Accounts Payable 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$990.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-30 | -$500.00K 10-Q · filed 2026-07-30 | -$338.00K derived: sum of 3 quarters · filed 2026-07-30 | -$1.56M derived: sum of 4 quarters · filed 2026-07-30 |
| 2026-03-31 | $490.00K 10-Q · filed 2026-05-05 | $652.00K derived: sum of 2 quarters · filed 2026-05-05 | -$569.00K derived: sum of 3 quarters · filed 2026-05-05 | -$2.21M derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-12-31 | $162.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | -$1.06M derived: sum of 2 quarters · filed 2026-03-05 | -$2.70M derived: sum of 3 quarters · filed 2026-07-30 | -$869.00K 10-K · filed 2026-03-05 |
| 2025-09-30 | -$1.22M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-30 | -$2.87M derived: sum of 2 quarters · filed 2026-07-30 | -$1.03M 10-Q · filed 2025-10-30 | -$653.00K derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-06-30 | -$1.64M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-30 | $190.00K 10-Q · filed 2026-07-30 | $568.00K derived: sum of 3 quarters · filed 2026-07-30 | $1.23M derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-03-31 | $1.83M 10-Q · filed 2026-05-05 | $2.21M derived: sum of 2 quarters · filed 2026-05-05 | $2.88M derived: sum of 3 quarters · filed 2026-05-05 | $3.04M derived: sum of 4 quarters · filed 2026-05-05 |
| 2024-12-31 | $378.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $1.04M derived: sum of 2 quarters · filed 2026-03-05 | $1.21M derived: sum of 3 quarters · filed 2026-03-05 | $1.14M 10-K · filed 2026-03-05 |
| 2024-09-30 | $663.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-30 | $833.00K derived: sum of 2 quarters · filed 2025-10-30 | $763.00K 10-Q · filed 2025-10-30 | $138.00K derived: sum of 4 quarters · filed 2025-10-30 |
| 2024-06-30 | $170.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-05 | $100.00K 10-Q · filed 2025-08-05 | -$525.00K derived: sum of 3 quarters · filed 2025-08-05 | $131.00K derived: sum of 4 quarters · filed 2025-08-05 |
| 2024-03-31 | -$70.00K 10-Q · filed 2025-05-14 | -$695.00K derived: sum of 2 quarters · filed 2025-05-14 | -$39.00K derived: sum of 3 quarters · filed 2025-05-14 | -$352.00K derived: sum of 4 quarters · filed 2025-05-14 |
| 2023-12-31 | -$625.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-06 | $31.00K derived: sum of 2 quarters · filed 2025-03-06 | -$282.00K derived: sum of 3 quarters · filed 2025-03-06 | $0.00 10-K · filed 2025-03-06 |
| 2023-09-30 | $656.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | $343.00K derived: sum of 2 quarters · filed 2024-11-06 | $625.00K 10-Q · filed 2024-11-06 | |
| 2023-06-30 | -$313.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | -$31.00K 10-Q · filed 2024-08-14 | ||
| 2023-03-31 | $282.00K 10-Q · filed 2024-05-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Mereo BioPharma Group plc (MREO) | $0.269B | -9.41 | |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| Greenwich LifeSciences, Inc. (GLSI) | United States | $0.267B | -15.02 |